Reported Sunday, Cullinan Therapeutics Reports Velinotamig Achieved Clinically Meaningful Disease Activity Improvement In 8 Of 9 Evaluable Refractory Lupus Patients, With Four Complete Renal Responses, In Data Presented At ACR Convergence 2026

Benzinga
Open on Benzinga